Archon Capital Management’s Biolase, Inc. BIOL Stock Holding History

Archon Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,070	Closed	-$1M	–	42
2020 Q1	$1M	Hold	1,070	–	–	0.37%	27
2019 Q4	$1.48M	Buy	1,070 +408	+62%	+$628K	0.25%	26
2019 Q3	$1.56M	Buy	662 +38	+6%	+$125K	0.37%	26
2019 Q2	$2.29M	Buy	624 +132	+27%	+$635K	0.42%	24
2019 Q1	$2.93M	Buy	492 +326	+196%	+$1.58M	0.8%	21
2018 Q4	$410K	Buy	+166	New	+$536K	0.17%	27

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ECM

ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Archon Capital Management's BIOL Position: Q2 2020 in Review

Archon Capital Management sold out of Biolase, Inc. (BIOL) in Q2 2020, closing a stake of 1,070 shares — an estimated $1M sold.

Archon Capital Management first reported a position in BIOL in Q4 2018 and held it in 6 quarters. The position peaked at $2.93M in Q1 2019. 21 funds tracked by Wall St. Rank hold BIOL as of Q2 2020.

Archon Capital Management reported no remaining Biolase, Inc. position as of Q2 2020 after selling out during the quarter.
Archon Capital Management sold 1,070 Biolase, Inc. shares in Q2 2020, an estimated $1M.
Archon Capital Management first reported a position in Biolase, Inc. in Q4 2018 and held it in 6 quarters.
Archon Capital Management's Biolase, Inc. position peaked at $2.93M in Q1 2019.
21 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2020.

Based on Archon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.